Clinical Trial Update: S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer [Phase 3]

View source ↗

Summary

Phase III SWOG trial comparing androgen deprivation therapy plus TAK-700 (Orteronel) versus ADT plus bicalutamide in metastatic prostate cancer has completed. R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Orteronel (Orteronel)
• bicalutamide (bicalutamide)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-09-08